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DJH, AMcS & GA – 2020 UPDATE 
For publication in the International Journal of Sports Medicine (IJSM), studies must have been 
conducted in accordance with recognised ethical standards and national/international laws. At 
the very first stage of paper submission, authors are required to confirm that these standards 
and laws have been adhered to by reading this editorial. Authors who do not provide any 
information regarding ethical approval will have their manuscripts rejected before it enters the 
peer-review process, without any option to resubmit.  
 
Research opportunities, methods and the contextual environment are continually evolving.  
While the four basic principles of biomedical ethics are, arguably, timeless [1], changes to data 
collection processes as well as research designs and settings bring changes to ethical 
considerations. In the original 2009 IJSM editorial [2], we described the ethical considerations 
embedded into national/international laws and provided specific guidance on the ethical issues 
which commonly arise in Sports Medicine research. In 2011, this information was updated to 
recognise the ethical principles of other professional associations and treaties when conducting 
research involving human participants [3]. Additional information was also provided on the use 
of Laboratory Animals in research, and on the links between sample size and research ethics. In 
the second update [4], published in 2014, we elaborated on the ethical issues relating to the 
investigation of doping agents; the use of animals for answering research questions that appear 
to be solely focussed on the enhancement of athletic performance; and sample size in the context 
of the burden to individual research participants. In 2016, we updated some of the guidelines to 
account for the changes made to the Declaration of Helsinki in 2013, covered the use of social 
media in research, provided guidance on how researchers can feed back their incidental and 
pertinent findings to research participants, covered some of the issues relating to studies 
involving children, and outlined the difference between a full and pilot study in terms of desired 
number of participants [5]. In the last update (2018), we clarified issues surrounding the use of 
a gatekeeper for accessing personal data on participants, as well as issues surrounding consent 
and the associated information to participants [6]. We covered other issues including, breaches 
of confidentiality, use of personal identifiable information, open access data and secondary 
analysis of data. We also highlighted the important considerations for use of placebos and 
research involving participant deception. 
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In this, our new update for 2020 onwards, we provide the following revisions and additions; 
• More detail on how to ensure consent/assent is truly informed. 
• More detail on issues in secondary data analysis projects, and in particular 
research using data already collected from athletes as part of their contractual 
obligations with club and/or country. 
• More detail on factors to consider when undertaking pre-study risk analysis and 
in study design. 
• Information on the application of the Principle of Justice [7]; with particular regard 
to gender imbalance in sampling.  
• Minor text changes to correct typographic errors and to clarify statements carried 
forward from previous versions. 
• Minor changes to the order and layout to enhance readability and usability and 
reduce areas of overlap. 
 
1. Research involving human participants 
All submitting authors should confirm that research involving human participants has been 
conducted ethically according to the principles of the World Medical Association Declaration of 
Helsinki [8]. The Declaration is intended to be read as a whole and every principle is equally 
important.  Those aspects of ethics, most pertinent to the types of research undertaken by sport 
and exercise scientists, are highlighted below:  
1.1. Basic principles. Respect for the dignity, rights, safety and wellbeing of all actual and 
potential participants, researchers, non-participating members of the public, and the 
environment takes precedence over scientific, or any other, considerations or 
interests. 
1.2. Ethical review. Before any substantive work begins (and before any amendments are 
made - after ethical approval), the research must be reviewed and approved by the 
relevant Research Ethics Committee/Institute Review Board (REC/IRB).  N.B. Since 
the primary purpose of ethical review is to protect the participants, ethical approval 
cannot be granted retrospectively.  
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1.3. Protocol. All aspects of the methods must be described clearly and be justifiable and 
appropriate. In writing the study protocol, the researcher must consider; 
a) ethical issues (with the Declaration of Helsinki as the principle reference), 
b) potential conflicts of interest and disclosure of any funding and sponsorship 
arrangements, institutional affiliations, and any other potential sources of conflict, 
c) the contribution of the work to the knowledge base in the area under study, 
d) arrangements for indemnifying participants, including compensation for anyone 
harmed as a result of participation, 
e) arrangements for treatment (or support), both immediate and in the longer term, 
for anyone injured or harmed as a result of participation. N.B. Researchers are not 
expected to provide treatment themselves (emergency First Aid/Responder type 
actions notwithstanding). Rather participants should be advised to seek help from 
their usual medical provider, 
f) arrangements for post-study access - by all participants - to interventions 
identified as beneficial in the study or access to other appropriate care or benefits. 
1.4. Consent. The potential participant’s choice (about participation) should be fully 
informed, free and private.   Informed consent/assent should be recorded in writing 
- Justification should be given for any exceptions to this.  Where consent/assent is 
oral, how and when that consent was given should still be formally documented and 
witnessed. Research that involves very young people, or others who are unable to 
consent (e.g. vulnerable adults), should involve consultation with an appropriate 
person and the assent of the participant (wherever the latter is possible). Research 
involving participants who are known to lack the mental capacity to give an informed 
consent may be undertaken only in accordance with local statute, e.g. [9,10].  In  
addition to all other considerations, the baseline principle that - having the 
characteristics, that impair informed consent, is a crucial aspect of eligibility (and 
hence, the research aims could not be achieved, with recruitment from any other 
population) - is expected to have been met. 
1.5. Information, for consent/assent, must be presented in accessible language/format and 
encompass (as a minimum) the;  
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a) researcher’s names and institutional affiliations 
b) aims of the research (i.e. why the work is being undertake), 
c) methods (i.e. what participants will be asked to do), 
d) sources of funding 
e) conflicts of interest 
f) anticipated benefits and potential risks 
g) potential discomfort 
h) right to decline the invitation to participate - without consequence 
i) the right to withdraw consent - without consequence - after consent but before 
data collection is completed 
j) the right to withdraw data after collection (if applicable) 
k) arrangements for data storage, sharing, retention/destruction etc. 
l) contact details for questions and/or complaints 
1.6. Conduct. Research must be conducted; 
a) in accordance with appropriate risk management (as identified in the pre-study 
risk assessment) 
b) by appropriately qualified researchers and support staff 
c) with skill and care 
d) in an appropriate setting 
e) in a way that protects the privacy of participants and the confidentiality of their 
personal information 
f) in accordance with applicable statute and frameworks/regulations of the country 
(or countries) in which the research is to be performed as well as international 
norms and standards. NB Country, or region, specific statute and 
frameworks/regulations often cover: aspects of research ethics; the collection, use 
and/or storage of human tissue; the protection of individuals that lack the capacity 
to consent; data access, processing and protection; and the use of drugs in 
research etc.  
1.7. Governance. Serious adverse events/reactions, occurring during the research, must 
be reported to the approving REC/IRB and the Sponsor in a timely period. 
DJH, AMcS & GA – 2020 UPDATE 
1.8. Use of Social Media. All research which involves the use of social media to recruit 
participants, conduct research or as a data source must: be ethically reviewed and 
approved by an appropriate ethics committee, ensure that the principles of informed 
consent; risks, burdens and benefits; and privacy and confidentiality are adhered to. 
Researchers should address the following issues; the practicalities of providing 
information, recording consent and collecting/using data; anonymity, privacy and 
confidentiality in a setting whereby information is publicly available from identifiable 
sources; the potential for harm and intrusion; data ownership and security; 
researcher identity.  
1.9. Pertinent and Incidental Findings. Pertinent findings are related to the variable or 
primary outcome(s) being studied and incidental findings are not related to the 
variable or primary outcome(s) being studied. Pertinent and incidental findings may 
be interesting or important to research participants and it is the responsibility of 
researchers to decide whether to feedback findings, to provide clear information to 
participants on their intentions, seek consent, respect autonomy and understand and 
manage expectations by having a practical feedback pathway that is adequately 
resourced and approved by the relevant IRB/REC. 
1.10. Participant involvement. In accordance with recommendations made by the Nuffield 
Council on Bioethics to the Health Research Authority [11], researchers should 
endeavour to involve children, young people and parents/guardians, as appropriate, 
in the design of research. Participant involvement in other aspects of the research 
such as the dissemination of findings is also good practice. Authors may conduct their 
research in accordance with principles detailed by professional associations and 
sources other than the World Medical Association Declaration of Helsinki such as the 
International Sociological Association’s (ISA) Code of Ethics [12]. It is recognised that 
differences in ethical principles may exist between professional associations and 
sources, e.g.: 
a) The ISA’s code of Ethics states that “The consent of research subjects and 
informants should be obtained in advance. Covert research should be avoided in 
principle, unless it is the only method by which information can be gathered, 
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and/or when access to the usual sources of information is obstructed by those in 
power.” [12].  
b) The UK Medical Research Council has outlined some basic principles of good 
research practice which may help to ensure that research is conducted ethically. 
These include planning, conduct, recording data, reporting and applying results 
[13].  
c) Relevant issues, not specifically raised in the Declaration of Helsinki include, for 
example: the use, calibration and maintenance of equipment, adherence to 
Control of Substances Hazardous to Health Regulations (and local/National 
equivalents), documentation of standard operating procedures, retention of data, 
publication policy, authorship, correction of errors and retraction of published 
findings and intellectual property rights. Authors are required to detail and justify, 
where aspects of their research abide by ethical principles set down by 
professional associations or sources that differ, in substance, from any of the 
principles in the Declaration of Helsinki, or this editorial.  
 
2. Author obligations 
By reading and citing this editorial, the author(s) confirm the following points are upheld [14]: 
2.1. The points, principles and practice guidance, contained in this editorial were 
considered and have been adhered to (the statement required under 1.10 c), above, 
not withstanding). 
2.2. That consent/assent, to participate was valid, in that potential participants were 
provided with adequate information, consent/assent was given voluntarily and that 
those providing consent/assent were competent to do so. 
2.3. Where research involved participants who were vulnerable or unable to provide 
consent, authors must confirm that the participants were appropriately identified, 
approached and recruited, there was justification for carrying out the research with 
these individuals and additional measures were put in place to ensure the research 
was ethical and complied with applicable statute. 
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2.4. Issues of privacy and confidentiality were considered carefully, as matters of ethics 
and not only to meet any minimum legal requirements. Where, “privacy is the 
protection of control over information about oneself; control over access to oneself, 
both physically and mentally; and control over one’s ability to make important 
decisions about family and lifestyle in order to be self-expressive and to develop 
varied relationships” [14]. And confidentiality is when the “participant discloses to the 
researcher information which the participant regards as confidential or secret [default 
assumption]; and the researcher undertakes (implicitly or explicitly) not to reveal this 
information to anyone who does not already possess it.” [14]. 
2.5. Researchers considered their own and the Sponsor’s, legal and ethical obligations if 
privacy and confidentiality are breached.  
2.6. If the confidential information that was provided as part of a research study has (or 
will be) accessed and processed for any other purposes, that confidentiality has been 
preserved by anonymising the information and that consent for that was obtained, or 
- where derogations allowing access and processing without consent (for example) 
are applicable - the terms of those were/will be complied with. 
2.7. Risks relating to harm, inconvenience, time and money, as well as any benefits to the 
participant, to other individuals, to the researchers and organisations were considered 
in a balanced fashion, communicated to the participants as part of the consent/asent 
process and appropriately managed.  
2.8. Likely variation in participant’s reaction to and experience of, interventions, outcome 
measures etc., arising from not only their physical and mental abilities, but, all other 
known determinants (such as gender, age, physical maturity etc.) were considered in 
all aspects of the design and methods. 
2.9. Participants were not exploited and particular groups were not discriminated from 
participation. 
2.10. There were appropriate governance arrangements and structures in place if 
participants were asked to donate biological material for use in future research, such 
as a “biobank”. These arrangements should involve appropriate consideration of broad 
consent, privacy and confidentiality, feedback to the participant of incidental findings, 
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storage of material, commercial involvement, donor involvement, intellectual 
property rights and local statute. 
2.11. Participants were informed of and consented/assented to, all aspects of data access 
and processing; i.e. the storage of data, including how and where the data is stored, 
the security of storage, how long data are stored for, what uses the data will have, 
who will have access to the data (other researchers, institution staff, general public) 
and any data sharing that may occur etc. 
 
3. Research Involving Animals 
Authors who cite this editorial confirm that research involving animals has been conducted 
ethically according to the principles of the Guide for the Care and Use of Laboratory Animals of 
the Institute for Laboratory Animal Research [15]. Again, the guide is intended to be read as a 
whole, but the basic obligations on the researcher are summarised below. The researcher must;  
3.1. Ensure the appropriateness of experimental methods 
3.2. Legally acquire animals  
3.3. Ensure that animals are properly housed and fed to ensure safe, hygienic and 
comfortable living conditions. 
3.4. Maintain a record of animal care 
3.5. Ensure that animal maintenance and research are carried out by qualified personnel, 
following all applicable legal statutes and regulations 
3.6. Administer appropriate pain management to minimize suffering, discomfort and pain 
 
The eighth edition of the Guide for the Care and Use of Laboratory Animals [16], published in 
2010, includes expanded coverage of the ethics of laboratory animal use; components of 
effective Animal Care and Use Programmes; and new guidelines for the housing, environment, 
and enrichment of terrestrial and aquatic animals, and for veterinary and clinical care [17]. 
Specifically: 
• The core foundation of the guide — replacement, refinement, and reduction. 
• An Animal Care and Use Programme 
• The performance standards approach for animal care and care practices 
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• The care and use of fish and other aquatic species 
• Housing space and enclosures for animals’ social needs 
• Environmental enrichment for the enhancement of animal well-being to provide sensory 
and motor stimulation and promote psychological health 
• Discussion of animal biosecurity practices 
 
4. Exercise protocols in animal research 
A useful document for any researcher interested in studying animals in an exercise context is 
the Resource Book of the American Physiological Society [18]. It is clear that the study of animals 
can help elucidate the mechanisms of exercise–related benefits to both human and animal 
health. Nevertheless, any animal study that has been specifically designed to answer a research 
question based solely on the enhancement of human athletic performance should include a clear 
explanation as to why such a study is necessary, and why it could not be undertaken on humans. 
This justification is important, not just from an ethical perspective, but is in keeping with the 
aim of maximising external validity in any study. 
 
5. Specific issues relevant to Sports Medicine and publishing in the IJSM: 
5.1. Secondary Data Analysis Projects.  Data are routinely collected from individuals for 
various purposes; e.g. an athlete’s physiological function, or health status, may be 
monitored (and corresponding data recorded) for training purposes.  Such data 
collection may be a contractual obligation for some.  Researchers must consider that 
data collected for one purpose (e.g. performance monitoring), cannot normally be 
accessed or processed for another purpose (e.g. research) unless explicit and 
informed, consent for the secondary data access and processing is obtained (and the 
research ethically approved), or local derogations permitting such access and 
processing without consent are adhered to.  This issue is particularly pertinent (and 
hence great care must be taken) where the data concerned was collected as part of 
a contractual obligation.  Researchers who are accessing, processing and/or storing 
data obtained from large accessible repositories should do so according to terms of 
the repository holder. 
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5.2. The use of placebo. The inclusion of a placebo group (whether the study involves 
athletes or not) may challenge the principle of equity and should only occur where 
there is genuine equipoise regarding the efficacy/effectiveness of the intervention 
under study. Participants should be randomly assigned, with adequate concealment 
approaches, to experimental or placebo groups and allocation should be blinded 
wherever possible. After a finite length of time those participants in the comparator 
group could be offered the experimental condition, and an experiment should 
normally be halted if it became clear that the placebo group was fairing more poorly 
[19]. In research where participants are patients or clients, extreme care must be 
taken to avoid the abuse of placebo. The use of placebo is generally acceptable only 
when there is equipoise concerning the intervention under study, any risk of harm is 
proportionate to the likely benefits and hence no proven treatment is withheld. 
5.3. Deception. The use of deception in research (e.g. in a pacing strategy study in which 
time trial distance is deceived) must be minimal and justified: 
a) Minimal, in the majority of studies while the purpose or aim of the study may require to 
be concealed, what participants will be asked to do, does not, and 
b) Justified, in that no reasonable alternative methods could be used to obtain the data 
required to achieve the aims.  In addition there should not normally be any anticipated 
pain or emotional distress for participants.  
c) Where there is deception, participants must be accurately informed of the nature, extent 
and purpose of the deception, as soon as is possible, and given the option to withdraw 
their data if they wish [20].   
5.4. Athletes as participants in studies on doping agents. 
In principle, recreational and elite athletes should not be recruited to participate in research 
that exposes them to violations of the World Anti-Doping Code [21]. However, there may 
be value of research into doping in sport and so a legitimate reason to recruit athletes as 
participants. Investigators who wish to recruit athletes as participants in research involving 
performance enhancing substances and methods should consider the following: 
a) Consultation with appropriate and relevant authorities (specific to each individual athlete)  
such as IRB/RECs, World Anti-Doping Agency (WADA), international sport federations 
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and national anti-doping organisations – to help protect recreational athletes, elite 
athletes and sport.  
b) An unfair advantage should not be afforded to a recreational or elite athlete participating 
in the research. 
c) “Adequate precautions should be taken so that the results of research are not misused 
and applied for doping” [21] 
d) Append the WADA letter entitled “Scientific research using elite athletes: WADA point of 
view” [22] to the participant information sheet to help fully inform participants who are 
recreational or elite athletes. 
6. Ethics and sample size. 
Statistical power and precision should be considered by all authors submitting to IJSM. 
Ideally an a priori estimation of the minimal sample size for adequate statistical power 
and/or adequate precision of a confidence interval should be reported. Post hoc statistical 
power estimations (based on the observed effect size in the study) are now frowned upon. 
Authors and reviewers of IJSM manuscripts should be aware of the following important 
points: 
6.1. The minimal sample size for adequate statistical power should be considered 
alongside the burden of the study procedures on individual participants/animals and 
the predicted importance of the study findings to the knowledge base as well as to 
the impact on real-world practice [23]. An unethical scenario is where many 
participants or animals have been substantially burdened by the study procedures, 
but the study findings have dubious clinical/practical importance. A “small” study 
might not be unethical, especially if participant burden is low and clinical/practical 
importance of the study findings are high, even if “statistical significance” has not 
been realised.  
6.2. For the importance of a study to be judged, it is imperative that the minimal 
clinically/practically important magnitude of change or difference is rationalised 
clearly and reported by authors [24]. We encourage authors to report the associated 
confidence interval(s), at least for the primary study outcomes. Authors who rely 
solely on statistical significance (i.e. the size of a p-value) to judge clinical/practical 
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importance will have their manuscripts rejected. It is important to recognise the 
difference between the minimal clinically important effect size/association and the 
minimal detectable effect. The latter is the lowest effect size or association that can 
be detected with a given precision and sample size whereas the former the the effect 
size or association that is important clinically/practically on the basis of potential for 
altering “hard” outcomes like morbidity or mortality. 
6.3. It is wholly inappropriate for a reviewer to criticise a study on the basis of a perceived 
small sample size without considering the above issues of participant burden and 
clinical/practical importance. Nevertheless, it is important for researchers to 
appreciate the possibility that an unusually large sample effect size was observed 
through the sampling error associated with a small sample size, sometimes referred 
to as “The Winners Curse” [25]. 
6.4. There are useful guidelines on what constitutes a pilot or feasibility study, e.g. [26].  
Such studies do not necessarily have to be powered to detect a certain effect size. 
Alternatively, they may be powered to detect, with adequate precision, a standard 
deviation for use to ultimately help estimate the required sample size for a substantive 
trial. 
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